Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Glutathione S-transferase T1 is a potential new target for the hepatic component of graft vs host disease after HSCT

Bone Marrow Transplantation volume 45, pages 774–775 (2010)Cite this article

Graft-vs-host disease remains a major complication after allogeneic hematopoietic SCT (HSCT) from an HLA identical donor. Development of GVHD results from donor T-cell responses to recipient mHAs due to polymorphisms between donor and recipient. Only a small number of human mHAs have been characterized although studies in mice suggest that a large number of them could be important in human transplantation. Human mHAs include some encoded by the Y chromosome genes and others encoded by autosomal genes.1 Nevertheless, there is a complete lack of studies addressing the B-cell response to mHAs in GVHD.

Glutathione S-transferase T1 (GSTT1) is a drug-metabolizing enzyme that belongs to the GST superfamily and is involved in detoxification processes. GSTT1 is highly expressed in liver, kidney, small intestine and erythrocytes, and modulation of its expression is induced by substrates such as BU and CHOP. GSTT1 is encoded by a single-copy gene on the human chromosome 22, which is absent in 20% of the Caucasian population because of a deletion that removes the entire gene.2 In the liver transplantation setting, we have reported that some GSTT1-negative patients who received a GSTT1-positive graft frequently develop a severe immune-mediated hepatitis, with the presence of anti-GSTT1 antibodies belonging to the IgG isotype.3 Similarly, kidney transplants carried out with the same donor–recipient GSTT1 mismatch are, in a proportion of cases, associated with the presence of anti-GSTT1 antibodies, deposits of C4d and signs of chronic rejection.4 We studied the role of GSTT1 as a potential new mHA in GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kollgaard T, Hadrup SR, Petersen SL, Masmas TN, Andersen MH, Spierings E et al. Natural T-cell responses against minor histocompatibility antigen (mHag) HY following HLA-matched hematopoietic cell transplantation: what are the requirements for a ‘good’ mHag? Leukemia 2008; 22: 1948–1951.

    Article  CAS  PubMed  Google Scholar 

  2. Landi S . Mammalian class theta GST and differential susceptibility to carcinogens: a review. Mutat Res 2000; 463: 247–283.

    Article  CAS  PubMed  Google Scholar 

  3. Aguilera I, Sousa JM, Gavilan F, Bernardos A, Wichmann I, Nuñez-Roldán A . Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation. Liver Transpl 2004; 10: 1166–1172.

    Article  PubMed  Google Scholar 

  4. Aguilera I, Alvarez-Marquez A, Gentil MA, Fernández-Alonso J, Fijo J, Saez C et al. Anti-Glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients. Nephrol Dial Transpl 2008; 23: 2393–2398.

    Article  CAS  Google Scholar 

  5. Wichmann I, Aguilera I, Sousa JM, Bernardos A, Garcia-Nuñez EJ, Vigil E et al. Antibodies against GSTT1 (glutathione S-transferase T1) in non-solid organ transplanted patients. Transfusion 2006; 46: 1505–1509.

    Article  CAS  PubMed  Google Scholar 

  6. Murata M, Warren EH, Riddell SR . A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003; 197: 1279–1289.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The study was supported by grants from Fondo de Investigaciones Sanitarias (FIS 05/0733, 05/0374) and Junta de Andalucía (PI-0332, CTS 2886).

Author information

Authors and Affiliations

  1. Immunology Service, Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Rocío, Sevilla, Spain

    I Aguilera, M J Martinez-Bravo & A Nuñez-Roldan

  2. Hematology Service, Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Rocío, Sevilla, Spain

    I Espigado, I Tallon & A Urbano-Ispizua

Authors
  1. I Aguilera
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Espigado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M J Martinez-Bravo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I Tallon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Urbano-Ispizua
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Nuñez-Roldan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Aguilera.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aguilera, I., Espigado, I., Martinez-Bravo, M. et al. Glutathione S-transferase T1 is a potential new target for the hepatic component of graft vs host disease after HSCT. Bone Marrow Transplant 45, 774–775 (2010). https://doi.org/10.1038/bmt.2009.206

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2009.206

This article is cited by

Search

Advanced search

Quick links